- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02417025
Innovative Delivery of Evidence Based Psychotherapy to Women With Military Sexual Trauma
Do You Really Expect Me to Get MST Care in a VA Where Everyone is Male? Innovative Delivery of Evidence Based Psychotherapy to Women With Military Sexual Trauma (MST)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The purpose of this project is to test, using mixed qualitative and quantitative assessment strategies, the efficacy of PE delivered via home-based telehealth (PE-HBT) versus PE delivered via standard service delivery (PE-SD) using a randomized, between groups, repeated measures design.
Objective 1: To compare, at post, 3 and 6-month follow-up, whether PE-HBT is superior to PE-SD across critical clinical and quality of life outcomes (i.e., PTSD, depression, quality of life) due to increased PE 'dosing' that results from improved session attendance and reduced attrition.
Hypothesis 1: In intent-to-treat analyses, PE-HBT will be more effective than PE-SD at improving clinical and quality of life outcomes at post, 3, and 6-month follow-up; improvement will correlate with session attendance, which will be higher in PE-HBT.
Objective 2: To compare at post-intervention whether PE-HBT is superior to PE-SD across critical process outcomes (e.g., session attendance, satisfaction, and treatment adherence).
Hypothesis 2: PE-HBT will yield better process outcomes than PE-SD post-intervention.
Exploratory Aims: (1) To determine if treatment adherence and other process variables mediate the relationship between treatment condition and clinical and quality of life outcomes as noted in Objective 1; and (2) To use qualitative interviewing methods to obtain data on Veterans' reactions, preferences, difficulties, and suggestions for MST services.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29401
- Ralph H. Johnson VAMC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- MST-related index event
- Diagnosis of PTSD-related MST
- Female
Exclusion Criteria:
- Having a household member of spouse who is already enrolled in the study
- Active psychosis or dementia
- Suicidal and/or homicidal ideation with clear intent
- Current substance dependence
- Concurrent enrollment in another clinical trial for PTSD or depression
- Unwilling to make regular appointments (note that if the participant has medical/transportation barriers that render her unable to make set appointments, this is not grounds for exclusion).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PE-HBT
Prolonged Exposure via home-based telehealth (i.e., completed using videoconferencing technology)
|
Prolonged Exposure
|
ACTIVE_COMPARATOR: PE-SD
Prolonged Exposure via standard delivery (i.e., completed in person at the therapist's office)
|
Prolonged Exposure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants Receiving Prolonged Exposure Treatment via Telemedicine with significantly decreased PTSD symptoms Compared to Number of Participants Receiving Prolonged Exposure Treatment with Standard In-Person Delivery
Time Frame: 36 weeks
|
36 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mini International Neuropsychiatric Interview (M.I.N.I.)
Time Frame: Baseline
|
The MINI is a brief structured interview that assesses the criteria for DSM-V Axis I diagnoses.
The MINI will be used to assess for a diagnosis of current depression, panic symptoms, generalized anxiety symptoms, eating disorders, psychotic symptoms and to screen for substance dependence.
|
Baseline
|
Mini International Neuropsychiatric Interview (M.I.N.I.)
Time Frame: 36 weeks
|
The MINI is a brief structured interview that assesses the criteria for DSM-V Axis I diagnoses.
The MINI will be used to assess for a diagnosis of current depression, panic symptoms, generalized anxiety symptoms, eating disorders, psychotic symptoms and to screen for substance dependence.
|
36 weeks
|
PTSD Checklist, 5th Version (PCL-5)
Time Frame: Baseline
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD.
The PCL-5 has a variety of purposes, including, monitoring symptom change during and after treatment, screening individuals for PTSD, and making a provisional PTSD diagnosis.
Description information provided by the National Center for PTSD.
|
Baseline
|
PTSD Checklist, 5th Version (PCL-5)
Time Frame: 13 weeks
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD.
The PCL-5 has a variety of purposes, including, monitoring symptom change during and after treatment, screening individuals for PTSD, and making a provisional PTSD diagnosis.
Description information provided by the National Center for PTSD.
|
13 weeks
|
PTSD Checklist, 5th Version (PCL-5)
Time Frame: 24 weeks
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD.
The PCL-5 has a variety of purposes, including, monitoring symptom change during and after treatment, screening individuals for PTSD, and making a provisional PTSD diagnosis.
Description information provided by the National Center for PTSD.
|
24 weeks
|
PTSD Checklist, 5th Version (PCL-5)
Time Frame: 36 weeks
|
The PCL-5 is a 20-item self-report measure that assesses the 20 DSM-5 symptoms of PTSD.
The PCL-5 has a variety of purposes, including, monitoring symptom change during and after treatment, screening individuals for PTSD, and making a provisional PTSD diagnosis.
Description information provided by the National Center for PTSD.
|
36 weeks
|
Veteran (VR) Short Form (SF) -12 Health Survey (VR-12)
Time Frame: Baseline
|
The VR-12 is short measure designed to assess participants' views on their current health, how they are feeling at this time point, and how well they are able to do their usual activities.
It also asks questions regarding how daily activities are/have been hindered by problems with their physical health.
|
Baseline
|
Veteran (VR) Short Form (SF) -12 Health Survey (VR-12)
Time Frame: 13 weeks
|
The VR-12 is short measure designed to assess participants' views on their current health, how they are feeling at this time point, and how well they are able to do their usual activities.
It also asks questions regarding how daily activities are/have been hindered by problems with their physical health.
|
13 weeks
|
Veteran (VR) Short Form (SF) -12 Health Survey (VR-12)
Time Frame: 24 weeks
|
The VR-12 is short measure designed to assess participants' views on their current health, how they are feeling at this time point, and how well they are able to do their usual activities.
It also asks questions regarding how daily activities are/have been hindered by problems with their physical health.
|
24 weeks
|
Veteran (VR) Short Form (SF) -12 Health Survey (VR-12)
Time Frame: 36 weeks
|
The VR-12 is short measure designed to assess participants' views on their current health, how they are feeling at this time point, and how well they are able to do their usual activities.
It also asks questions regarding how daily activities are/have been hindered by problems with their physical health.
|
36 weeks
|
Index of Functional Impairment (IFI)
Time Frame: Baseline
|
The Index of Functional Impairment (IFI) is a self-report inventory of functional impairment.
Patients rate their level of functioning across multiple psychosocial domains including romantic relationships, employment, and educational achievement.
|
Baseline
|
Index of Functional Impairment (IFI)
Time Frame: 13 weeks
|
The Index of Functional Impairment (IFI) is a self-report inventory of functional impairment.
Patients rate their level of functioning across multiple psychosocial domains including romantic relationships, employment, and educational achievement.
|
13 weeks
|
Index of Functional Impairment (IFI)
Time Frame: 24 weeks
|
The Index of Functional Impairment (IFI) is a self-report inventory of functional impairment.
Patients rate their level of functioning across multiple psychosocial domains including romantic relationships, employment, and educational achievement.
|
24 weeks
|
Index of Functional Impairment (IFI)
Time Frame: 36 weeks
|
The Index of Functional Impairment (IFI) is a self-report inventory of functional impairment.
Patients rate their level of functioning across multiple psychosocial domains including romantic relationships, employment, and educational achievement.
|
36 weeks
|
Treatment Credibility Questionnaire
Time Frame: 13 weeks
|
This questionnaire is used to assess for differences in outcome expectancy using treatment credibility scales.
The questionnaire asks how the participant feels about the current treatment she is receiving, how logical it seems, how likely she would be to recommend it to a friend, and how successful she believes it is in decreasing different symptoms of PTSD, such as fear.
|
13 weeks
|
Charleston Psychiatric Outpatient Satisfaction Scale (CPOSS)
Time Frame: 13 weeks
|
The CPOSS is a 16-item questionnaire that assesses the participant's attitudes about the Charleston VA facility, such as the quality of care she received at the hospital, the helpfulness of the secretary, clear and correct monthly documentation of problems in her medical record, etc.
|
13 weeks
|
Alcohol Use Disorder Identification Test (AUDIT)
Time Frame: Baseline
|
The AUDIT is a 10-item measure that assesses the level of the participant's drinking.
Questions include how many drinks a participant has during a day or on occasions, possible harmful consequences of drinking, and feelings of remorse about drinking.
|
Baseline
|
Alcohol Use Disorder Identification Test (AUDIT)
Time Frame: 13 weeks
|
The AUDIT is a 10-item measure that assesses the level of the participant's drinking.
Questions include how many drinks a participant has during a day or on occasions, possible harmful consequences of drinking, and feelings of remorse about drinking.
|
13 weeks
|
Alcohol Use Disorder Identification Test (AUDIT)
Time Frame: 24 weeks
|
The AUDIT is a 10-item measure that assesses the level of the participant's drinking.
Questions include how many drinks a participant has during a day or on occasions, possible harmful consequences of drinking, and feelings of remorse about drinking.
|
24 weeks
|
Alcohol Use Disorder Identification Test (AUDIT)
Time Frame: 36 weeks
|
The AUDIT is a 10-item measure that assesses the level of the participant's drinking.
Questions include how many drinks a participant has during a day or on occasions, possible harmful consequences of drinking, and feelings of remorse about drinking.
|
36 weeks
|
Drug Abuse Screening Test (DAST-10)
Time Frame: Baseline
|
The DAST-10 is a 10-item measure designed to assess for illegal drug use (not including alcohol) for the past month.
|
Baseline
|
Drug Abuse Screening Test (DAST-10)
Time Frame: 13 weeks
|
The DAST-10 is a 10-item measure designed to assess for illegal drug use (not including alcohol) for the past month.
|
13 weeks
|
Drug Abuse Screening Test (DAST-10)
Time Frame: 24 weeks
|
The DAST-10 is a 10-item measure designed to assess for illegal drug use (not including alcohol) for the past month.
|
24 weeks
|
Drug Abuse Screening Test (DAST-10)
Time Frame: 36 weeks
|
The DAST-10 is a 10-item measure designed to assess for illegal drug use (not including alcohol) for the past month.
|
36 weeks
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline
|
The PSQI is a 19-item commonly used and well validated self-report measure of sleep quality and disturbance.
Scores on the PSQI range from 0 to 21, with rating of 5 or higher indicative of poor sleep quality.
|
Baseline
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 13 weeks
|
The PSQI is a 19-item commonly used and well validated self-report measure of sleep quality and disturbance.
Scores on the PSQI range from 0 to 21, with rating of 5 or higher indicative of poor sleep quality.
|
13 weeks
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 24 weeks
|
The PSQI is a 19-item commonly used and well validated self-report measure of sleep quality and disturbance.
Scores on the PSQI range from 0 to 21, with rating of 5 or higher indicative of poor sleep quality.
|
24 weeks
|
Pittsburgh Sleep Quality Index (PSQI)
Time Frame: 36 weeks
|
The PSQI is a 19-item commonly used and well validated self-report measure of sleep quality and disturbance.
Scores on the PSQI range from 0 to 21, with rating of 5 or higher indicative of poor sleep quality.
|
36 weeks
|
Sexual Assault Related Mental Contamination Scale (SARA)
Time Frame: Baseline
|
This abbreviated version of the 80-item SARA scale assesses the participant's perceptions of her sexual assault/rape.
|
Baseline
|
Sexual Assault Related Mental Contamination Scale (SARA)
Time Frame: 13 weeks
|
This abbreviated version of the 80-item SARA scale assesses the participant's perceptions of her sexual assault/rape.
|
13 weeks
|
Sexual Assault Related Mental Contamination Scale (SARA)
Time Frame: 24 weeks
|
This abbreviated version of the 80-item SARA scale assesses the participant's perceptions of her sexual assault/rape.
|
24 weeks
|
Sexual Assault Related Mental Contamination Scale (SARA)
Time Frame: 36 weeks
|
This abbreviated version of the 80-item SARA scale assesses the participant's perceptions of her sexual assault/rape.
|
36 weeks
|
Beck Depression Inventory - II (BDI-II)
Time Frame: Baseline
|
Beck Depression Inventory-II is a 21 item measure of depressive severity with higher total scores indicative of more severe depression.
|
Baseline
|
Beck Depression Inventory - II (BDI-II)
Time Frame: 13 weeks
|
Beck Depression Inventory-II is a 21 item measure of depressive severity with higher total scores indicative of more severe depression.
|
13 weeks
|
Beck Depression Inventory - II (BDI-II)
Time Frame: 24 weeks
|
Beck Depression Inventory-II is a 21 item measure of depressive severity with higher total scores indicative of more severe depression.
|
24 weeks
|
Beck Depression Inventory - II (BDI-II)
Time Frame: 36 weeks
|
Beck Depression Inventory-II is a 21 item measure of depressive severity with higher total scores indicative of more severe depression.
|
36 weeks
|
Clinical Administrated PTSD Scale (CAPS)
Time Frame: Baseline
|
The Clinician Administered PTSD (Posttraumatic stress disorder) Scale (CAPS) is a 30-item structured interview that corresponds to the Diagnostic and Statistical Manual of Mental Disorders, 5th Version (DSM-V) criteria for PTSD.
The CAPS can be used to make a current (past month) or lifetime diagnosis of PTSD or to assesses symptoms over the past week.
|
Baseline
|
Clinical Administrated PTSD Scale (CAPS)
Time Frame: 13 weeks
|
The Clinician Administered PTSD (Posttraumatic stress disorder) Scale (CAPS) is a 30-item structured interview that corresponds to the Diagnostic and Statistical Manual of Mental Disorders, 5th Version (DSM-V) criteria for PTSD.
The CAPS can be used to make a current (past month) or lifetime diagnosis of PTSD or to assesses symptoms over the past week.
|
13 weeks
|
Clinical Administrated PTSD Scale (CAPS)
Time Frame: 24 weeks
|
The Clinician Administered PTSD (Posttraumatic stress disorder) Scale (CAPS) is a 30-item structured interview that corresponds to the Diagnostic and Statistical Manual of Mental Disorders, 5th Version (DSM-V) criteria for PTSD.
The CAPS can be used to make a current (past month) or lifetime diagnosis of PTSD or to assesses symptoms over the past week.
|
24 weeks
|
Clinical Administrated PTSD Scale (CAPS)
Time Frame: 36 weeks
|
The Clinician Administered PTSD (Posttraumatic stress disorder) Scale (CAPS) is a 30-item structured interview that corresponds to the Diagnostic and Statistical Manual of Mental Disorders, 5th Version (DSM-V) criteria for PTSD.
The CAPS can be used to make a current (past month) or lifetime diagnosis of PTSD or to assesses symptoms over the past week.
|
36 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Ronald E Acierno, PhD, Ralph H. Johnson VA Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00034989
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mental Disorders
-
Kansas State UniversityAugusta University; Dartmouth College; University of CincinnatiEnrolling by invitationMental Disorders, Severe | Mental Illness PersistentUnited States
-
VA Boston Healthcare SystemUS Department of Veterans AffairsCompletedMental Health DisordersUnited States
-
Virginia Commonwealth UniversityCompletedMental Health DisordersUnited States
-
Johns Hopkins UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...CompletedMental Health DisordersCongo
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedMental Health DisordersNorway
-
York UniversityCanadian Institutes of Health Research (CIHR); North York General HospitalCompletedMental Health DisordersCanada
-
University of ManchesterEuropean Research CouncilRecruitingMental Disorders, SevereUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Active, not recruitingMental Disorders, SevereSpain
-
University of North Carolina, Chapel HillU.S. Department of JusticeCompletedMental Disorders, SevereUnited States
-
Liga Romana pentru Sanatate MintalaPsychiatric Hospital for Chronic Patients Siret, Suceava, RomaniaUnknown
Clinical Trials on PE
-
VA Office of Research and DevelopmentCompletedPosttraumatic Stress Disorders | Chronic InsomniaUnited States
-
VA Office of Research and DevelopmentDefense Centers of Excellence for Psychological Health and Traumatic Brain...RecruitingPosttraumatic Stress DisorderUnited States
-
Harvard School of Public Health (HSPH)Judge Baker Children's CenterCompletedMood Disorders | Anxiety Disorders | Attention Deficit and Disruptive Behavior Disorders | Autistic Disorder | Conduct Disorder | Oppositional Defiant DisorderUnited States
-
Medical University of South CarolinaGeorgia State UniversityCompletedAnxiety Disorders | Stress Disorders, Post-Traumatic | Mental Disorder | Traumatic Stress DisorderUnited States
-
Oslo University HospitalCompleted
-
Research Foundation for Mental Hygiene, Inc.University of Colorado, Boulder; Harvard UniversityCompletedPosttraumatic Stress Disorder (PTSD)United States
-
VA Office of Research and DevelopmentCompleted
-
University of MichiganMichigan Department of Health and Human ServicesCompleted
-
Sunnybrook Health Sciences CentreNorth York General HospitalRecruiting
-
Universidad de ZaragozaUniversity of ValladolidCompleted